Literature DB >> 11978420

High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo.

Ali H Mesiwala1, Lindi Farrell, H Jurgen Wenzel, Daniel L Silbergeld, Lawrence A Crum, H Richard Winn, Pierre D Mourad.   

Abstract

High-intensity focused ultrasound (HIFU) has been shown to generate lesions that destroy brain tissue while disrupting the blood-brain barrier (BBB) in the periphery of the lesion. BBB opening, however, has not been shown without damage, and the mechanisms by which HIFU induces BBB disruption remain unknown. We show that HIFU is capable of reversible, nondestructive, BBB disruption in a targeted region-of-interest (ROI) (29 of 55 applications; 26 of 55 applications showed no effect); this opening reverses after 72 h. Light microscopy demonstrates that HIFU either entirely preserves brain architecture while opening the BBB (18 of 29 applications), or generates tissue damage in a small volume within the region of BBB opening (11 of 29 applications). Electron microscopy supports these observations and suggests that HIFU disrupts the BBB by opening capillary endothelial cell tight junctions, an isolated ultrastructural effect that is different from the mechanisms through which other (untargeted) modalities, such as hyperosmotic solutions, hyperthermia and percussive injury disrupt the BBB.

Entities:  

Keywords:  Non-programmatic

Mesh:

Year:  2002        PMID: 11978420     DOI: 10.1016/s0301-5629(01)00521-x

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  67 in total

Review 1.  Ultrasound enhanced drug delivery to the brain and central nervous system.

Authors:  Meaghan A O'Reilly; Kullervo Hynynen
Journal:  Int J Hyperthermia       Date:  2012       Impact factor: 3.914

2.  Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.

Authors:  Muna Aryal; Natalia Vykhodtseva; Yong-Zhi Zhang; Nathan McDannold
Journal:  J Control Release       Date:  2015-02-24       Impact factor: 9.776

Review 3.  Ultrasonic drug delivery--a general review.

Authors:  William G Pitt; Ghaleb A Husseini; Bryant J Staples
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

4.  Can ultrasound solve the transport barrier of the neural retina?

Authors:  Liesbeth Peeters; Ine Lentacker; Roosmarijn E Vandenbroucke; Bart Lucas; Joseph Demeester; Niek N Sanders; Stefaan C De Smedt
Journal:  Pharm Res       Date:  2008-07-23       Impact factor: 4.200

Review 5.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Drug delivery across the blood-brain barrier using focused ultrasound.

Authors:  Alison Burgess; Kullervo Hynynen
Journal:  Expert Opin Drug Deliv       Date:  2014-03-20       Impact factor: 6.648

Review 7.  Evaluating the safety profile of focused ultrasound and microbubble-mediated treatments to increase blood-brain barrier permeability.

Authors:  Dallan McMahon; Charissa Poon; Kullervo Hynynen
Journal:  Expert Opin Drug Deliv       Date:  2019-01-29       Impact factor: 6.648

8.  Targeted drug delivery with focused ultrasound-induced blood-brain barrier opening using acoustically-activated nanodroplets.

Authors:  Cherry C Chen; Paul S Sheeran; Shih-Ying Wu; Oluyemi O Olumolade; Paul A Dayton; Elisa E Konofagou
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

9.  MR-guided transcranial brain HIFU in small animal models.

Authors:  B Larrat; M Pernot; J-F Aubry; E Dervishi; R Sinkus; D Seilhean; Y Marie; A-L Boch; M Fink; M Tanter
Journal:  Phys Med Biol       Date:  2009-12-17       Impact factor: 3.609

Review 10.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.

Authors:  Muna Aryal; Costas D Arvanitis; Phillip M Alexander; Nathan McDannold
Journal:  Adv Drug Deliv Rev       Date:  2014-01-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.